Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of efavirenz on the pharmacokinetics of BMS-790052 in healthy subjects
NL-OMON36747Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of daclatasvir and efavirenz in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Feb 2011; status: active, not recruiting.
02
Drugs
daclatasvirefavirenz
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON36747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36747.